

ONLINE FIRST PUBLICATION

Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs number provided. Mandatory typesetting and proofreading will commence with regular print and online publication of the online first papers of the *SMJ*.

Improved adrenal vein sampling from a dedicated programme: experience of a low-volume single centre in Singapore

Min-On Tan^{1,*}, MBBS, FRCR, Troy Hai Kiat Puar^{2,*}, MBBS, MRCP,
Saravana Kumar Swaminathan^{1,3}, MBBS, FRCR, Yu-Kwang Donovan Tay⁴, MBBS, MRCP,
Tar Choon Aw⁵, MBBS, FRCPA, David Yurui Lim¹, MBBS, FRCR,
Haiyuan Shi¹, MBBS, FRCR, Lily Mae Quevedo Dacay², MD, Meifen Zhang^{2,6}, MBBS, MRCP,
Joan Joo Ching Khoo², MBBS, FRCP, Keng Sin Ng^{1,7}, MBBS, FRCR

¹Department of Radiology, ²Department of Endocrinology, Changi General Hospital,
³Department of Neuroradiology, National Neuroscience Institute, ⁴Department of General
Medicine, Sengkang General Hospital, ⁵Laboratory Medicine, Changi General Hospital,
Singapore, ⁶William Harvey Research Institute, Queen Mary University of London, London,
England, United Kingdom, ⁷Mount Alvernia Hospital, Singapore

*These authors contributed equally as first authors in this work.

Correspondence: Dr Min-On Tan, Senior Resident, Department of Radiology, Changi General Hospital, 2 Simei Street 3, Singapore 529889. minon.tan@mohh.com.sg

Singapore Med J 2020, 1–18

<https://doi.org/10.11622/smedj.2020171>

Published ahead of print: 2 December 2020

Online version can be found at
<http://www.smj.org.sg/online-first>

INTRODUCTION

Primary aldosteronism (PA) affects 5%–10% of all patients with hypertension. About half of these patients have unilateral disease that can be cured with adrenalectomy.^(1,2) Adrenal vein sampling (AVS) is crucial for identifying unilateral PA,⁽³⁾ but it is operator dependent and technically difficult. While excellent AVS rates have been reported in high-volume specialised centres,^(4,5) most other institutions worldwide have cannulation rates as low as 31%–61%,^(6,7) leading to missed opportunities to cure. While surgery ameliorates the risk of cardiovascular disease, atrial fibrillation and death, patients treated with medications remain at an increased risk of complications,^(8,9) further highlighting the importance of identifying unilateral PA.

There are some alternatives to AVS, such as functional imaging using ¹¹C-metomidate positron emission tomography/computed tomography. It is a non-invasive alternative⁽¹⁰⁾ but has not been validated in large studies and is not widely available.⁽¹¹⁾ Using the computed tomography (CT) approach alone to identify unilateral disease led to similar blood pressure improvements post surgery compared to AVS in a randomised control trial.⁽¹²⁾ However, more patients in the CT arm failed to have cure of PA.⁽¹³⁾ Furthermore, CT diagnosis can lead to false conclusions in 37.8% of patients.^(14,15) Ultimately, having an effective AVS service is essential for optimising treatment of PA.

Several centres have utilised novel methods, such as the rapid cortisol assay,⁽¹⁶⁻¹⁸⁾ to improve AVS success, with mixed results.⁽¹⁹⁻²¹⁾ At our institution, we reviewed our AVS practice and incorporated several strategies in our programme to improve AVS rates. We herein report the success rates of our AVS programme, which was initiated in 2015. We also suggest practical measures that can be adopted by other low-volume centres worldwide to achieve similar success.

METHODS

We conducted a retrospective study of all patients who underwent AVS in our referral centre, Changi General Hospital, Singapore, from 1998 to 2019. AVS success rates before and after the implementation of an AVS programme in 2015 were assessed. Patient medical records were reviewed, and data on demographics, comorbidities, biochemistry, plasma renin activity (PRA) and plasma aldosterone concentration (PAC) was collected. Before hormonal tests, antihypertensive medications that interfere with the renin-angiotensin-aldosterone system were discontinued for at least two weeks in most patients, and potassium-sparing diuretics were stopped at least six weeks in all patients. Hypokalaemia was corrected with potassium supplementation, targeting a serum potassium level of ≥ 3.5 mmol/L. Patients underwent a seated saline infusion test, with a post-saline PAC level of ≥ 140 pmol/L confirming the diagnosis of PA. PRA and PAC were determined in all patients based on previous methodology.^(22,23) The lower limit of PRA was 0.15 ng/mL per hour before 2016 and 0.6 ng/mL per hour from 2017 onwards.

The study was approved by the local ethics committee, who waived the requirement for informed consent from patients seen before November 2017, while consent was taken for all patients after November 2017. All patients fulfilled the diagnostic criteria for PA according to the Endocrine Society guidelines,⁽²⁾ as we previously reported.⁽²²⁾ All patients underwent thin-section CT. Unilateral adenoma was defined as the presence of a unilateral nodule with a diameter of ≥ 8 mm, with a normal contralateral adrenal gland.

Sequential AVS under continuous corticotropin stimulation has been performed since 1998, with corticotropin infusion (50 mcg per hour) started at least 30 minutes before the start of the procedure. Adrenal veins were sequentially cannulated via a right femoral vein vascular sheath, and the catheter tip position was verified with an injection of non-ionic contrast medium. Blood was sampled from both adrenal veins and the infra-renal inferior vena cava (IVC). In

2015, potential pitfalls with previous AVS were identified, and an AVS programme was implemented and several measures were put in place: (1) a dedicated interventional radiologist, assigned to perform or supervise all the procedures; (2) routine contrast-enhanced CT imaging, used for assessment of adrenal vein anatomy prior to AVS; (3) use of at least a 4-French (Fr) Cobra catheter for the right adrenal vein cannulation (routinely attempted first) and 4-Fr Simmons 2 glide catheter for the left adrenal vein cannulation, with a check venogram to confirm the position; (4) routine creation of side holes close to the catheter tips; (5) gentle aspiration of blood to reduce risk of sampled veins collapsing during the procedure; (6) two right adrenal vein specimens during each AVS (initiated from 2016), involving repositioning the catheter with a recheck venogram; (7) 'rapid' cortisol reporting obtained by dispatching AVS serum cortisol to the laboratory and immediate analysis at neat and 1:20 dilution; (8) keeping femoral vein sheath *in situ* post procedure, with a view to repeat AVS immediately after if cortisol results indicate failure of cannulation; (9) computerised labels for each sample: 'right #1 adrenal vein', 'right #2 adrenal vein', 'left adrenal vein' and 'IVC'; and (10) collaboration with the laboratory to ensure that absolute values were reported for all cortisol and aldosterone samples.

We evaluated for improvement in the rate of successful bilateral cannulation before and after AVS programme implementation. We also assessed the selectivity index (SI), proportion of patients identified with unilateral PA, and concordance of AVS with CT. Adrenal vein cannulation was deemed successful if the SI was > 3 as recommended by an expert consensus.⁽²⁴⁾ The SI was calculated by taking the ratio of cortisol levels in the adrenal vein to that in the IVC. After 2016, multiple samples were taken from the right adrenal vein, and we assessed the utility of this intervention. Lateralisation ratio was calculated using the aldosterone-to-cortisol ratio between both adrenal veins. A lateralisation ratio of ≥ 4 was consistent with unilateral PA, while ≤ 2 was consistent with bilateral PA. In patients with ratios

between 2 and 4, AVS results were discussed at a multidisciplinary meeting for the final decision. Because absolute values of cortisol and aldosterone are required for interpretation of AVS results, failure of the laboratory to provide absolute values was noted and AVS was taken to be unsuccessful.

Statistical analyses were performed using IBM SPSS Statistics 21.0 (IBM Corp, Armonk, NY, USA). Continuous variables were expressed as median (interquartile range [IQR]) and categorical variables were expressed as number and percentage. Continuous variables were analysed using Mann-Whitney *U* test and categorical variables were analysed with Fisher's exact test. All tests were two-tailed, with differences considered to be significant when $p < 0.05$.

RESULTS

A total of 104 AVS procedures were conducted in 96 patients from 1998 to 2019 in a single tertiary centre (Table I). Four patients were excluded (one patient did not provide consent, one patient had AVS for Cushing's syndrome due to primary pigmented nodular adrenocortical disease, and two patients had insufficient medical information). All patients had hypertension with duration of 8 (4–16) years and baseline systolic blood pressure of 156 (145–170) mmHg while on a median of 2.0 (1.0–3.0) antihypertensive medications. At baseline, PAC was 713.6 (477.0–1,080.0) pmol/L and did not differ before and after programme implementation. PRA was lower in patients before 2016, which was contributed to by the change in the lowest reported value of PRA after 2016. Otherwise, the baseline characteristics of patients before and after programme implementation did not differ greatly, except for a lower prevalence of patients with stroke and a larger proportion of patients with bilateral normal adrenals on CT undergoing AVS post programme.

Table I. Baseline characteristics of patients pre- and post-programme implementation (n = 96).

Characteristic	No. (%) / median (interquartile range)			p-value
	Before programme (n = 37*)	After programme (n = 59)	Total (n = 96)	
Age (yr)	50.9 (46.9–57.7)	52.0 (43.4–61.5)	51.2 (43.6–61.1)	0.95
Female gender	15 (40.5)	18 (30.5)	33 (34.4)	0.38
Ethnicity				0.14
Chinese	29 (78.4)	48 (81.4)	77 (80.2)	
Malay	4 (10.8)	1 (1.7)	5 (5.2)	
Indian	0 (0)	3 (5.1)	3 (3.1)	
Others	4 (10.8)	7 (11.9)	11 (11.5)	
Body mass index (kg/m ²)	25.8 (22.4–29.0)	26.4 (23.7–29.0)	26.1 (23.5–29.0)	0.39
Systolic BP (mmHg)	160 (150–170)	153 (141–163)	156 (145–170)	0.06
Diastolic BP (mmHg)	87 (80–100)	88 (81–99)	88 (80–99)	0.69
No. of BP medications	2.0 (1.0–3.0)	2.0 (1.0–3.0)	2 (1.0–3.0)	0.87
BP medications (DDD)	2.3 (1.2–3.3)	2.1 (1.0–4.0)	2.3 (1.1–3.9)	0.72
Lowest serum potassium recorded	2.5 (2.1–2.7)	2.8 (2.4–3.0)	2.7 (2.3–3.0)	0.002
Potassium during AVS	3.3 (3.0–3.6)	3.6 (3.2–3.9)	3.4 (3.1–3.8)	0.07
Creatinine during AVS	78 (66–98)	85 (69–99)	81 (67–99)	0.34
PAC (pmol/L)	739.2 (532.5–1,158.1)	687.0 (467.0–1,074.0)	713.6 (477.0–1,080.0)	0.36
PRA (ng/mL/hr)	0.20 (0.20–0.30)	0.60 (0.20–0.60)	0.40 (0.20–0.60)	< 0.001
ARR	2,771.9 (2,155.9–4,368.2)	1,316.7 (761.5–2,533.3)	2,019 (947.8–3,275.1)	< 0.001
Post-SIT PAC (pmol/L)	455.0 (281.0–714.0)	429.4 (321.4–630.8)	443.2 (338.0–681.3)	0.36
Duration of hypertension (yr)	9 (4–17)	8 (4–16)	8 (4–16)	0.73
Ischaemic heart disease	5 (13.5)	5 (8.5)	10 (10.4)	0.50
Chronic kidney disease	3 (8.1)	2 (3.4)	5 (5.2)	0.37
Stroke	9 (24.3)	3 (5.1)	12 (12.5)	0.009
Hyperlipidaemia	22 (59.5)	26 (44.1)	48 (50.0)	0.21
Diabetes mellitus	15 (40.5)	17 (28.8)	32 (33.3)	0.27
Atrial fibrillation	4 (10.8)	2 (3.4)	6 (6.3)	0.20
Presence of hypokalaemia	37 (100.0)	56 (94.9)	93 (96.9)	0.28
Abnormal CT findings				0.002
Unilateral adenoma	32 (86.5)	41 (69.5)	73 (76.0)	

Bilateral abnormal	5 (13.5)	3 (5.1)	8 (8.3)	
Bilateral normal	0 (0)	15 (25.4)	15 (15.6)	

**One patient subsequently underwent AVS post-programme implementation. ARR: aldosterone-renin ratio; AVS: adrenal vein sampling; BP: blood pressure; DDD: daily defined dosage; PAC: plasma aldosterone concentration; PRA: plasma renin activity; SLT: saline-loading test*

41 AVS procedures were done in 37 patients from 1998 to 2014 (2.4 procedures per year), and this increased to 63 procedures in 60 patients from 2015 to 2019 (12.6 procedures per year) (Figs. 1 & 2). After implementation of the AVS programme, bilateral successful cannulation improved from 43.9% (18/41) to 100.0% (63/63), $p < 0.01$ (Appendix, Supplementary Table I). Before programme implementation, failure of right adrenal vein cannulation occurred in 12 (29.3%) of 41 procedures, while failure of left adrenal vein cannulation occurred in 1 (2.4%) procedure. In 10 (24.4%) procedures, there was bilateral cannulation failure. In 8 (19.5%) procedures, laboratory errors contributed to failure of AVS. Errors included failure to provide absolute levels of cortisol or aldosterone, or failure to send samples of both cortisol and aldosterone from each site. After programme implementation, there was an increase in SI in both the right adrenal vein from 3.9 (1.0–21.5) to 23.5 (17.1–32.7) ($p < 0.001$) and the left adrenal vein from 10.0 (4.5–19.4) to 18.1 (12.3–23.8) ($p < 0.001$).

After 2016, two right adrenal vein samples were taken; in 8 (12.7%) cases, the second right adrenal sample was successful, whereas the first sample was not. Hence, this additional sample avoided an additional procedure in 12.7% of cases. Improved AVS success led to more patients ($p < 0.01$) identified with unilateral PA, from 12 (32.4%) out of 37 patients to 40 (66.7%) out of 60 patients (Fig. 1b). In three patients, there was bilateral aldosterone suppression despite successful bilateral cannulation, and repeat AVS subsequently confirmed that these three patients had unilateral PA. These three cases have been reported separately.⁽²⁵⁾ In total, 76 patients had a successful AVS procedure. CT and AVS led to concordant findings in only 49 (64.5%) of 76 patients (Fig. 3). In 15 (19.7%) cases, AVS showed bilateral

hypersecretion despite a clear unilateral adenoma, and these patients may have undergone surgery that would not be curative.

Importantly, there were 4 (5.3%) cases where AVS and CT lateralised to opposite sides. One was a 34-year-old patient whose CT image showed left adrenal gland thickening (Appendix, Supplementary Fig. 1 & Table II). AVS results showed hypersecretion on the right side. Two sequential right adrenal samples were congruous, making it unlikely that the right and left samples were swapped. One year after right adrenalectomy, there was biochemical cure of PA. His blood pressure was 120/83 mmHg on losartan 50 mg daily.

DISCUSSION

We demonstrated that a dedicated effort to implement an AVS programme can improve success rates in a low-volume centre, resulting in more patients being offered curative unilateral adrenalectomy. Although some interventions such as rapid cortisol assays can improve AVS success, the response to such interventions has been variable, and they are not possible without certain infrastructure.^(6,7) Our success was likely attributable to the multiple interventions made as opposed to a single intervention. These measures can be adopted in many centres worldwide to achieve similar success.

Rapid cortisol assays can improve AVS success by providing immediate feedback of successful cannulation to the operator,^(7,17,26) with some assays providing results within six minutes.^(16,27) However, this is currently not widely available. As an alternative, we engaged our laboratory to provide urgent cortisol reporting. Samples were despatched directly to the laboratory, and designated staff ran the cortisol assays immediately (both neat and diluted at 1:20). For serum samples, special BD Vacutainer® rapid serum tubes can be obtained to allow clotting of blood within five minutes. Alternatively, plasma cortisol can be used instead. The total turnaround time is often within an hour, which allows the patient to be wheeled back to

the angiography suite if needed, with the venous sheath *in situ*. Notably, while urgent cortisol reporting was useful in our early experience, none of the recent 30 procedures since 2018 required a repeat AVS. We also noted that early AVS failures resulted from lack of absolute values reported for cortisol or aldosterone. Close collaboration with the laboratory ensured that this was made routine subsequently.

We introduced a practice of routinely sending two samples from the right adrenal vein for several reasons. It can be difficult to confirm correct catheter placement with the post-contrast venogram alone. In 12.7% of our cases, the first right adrenal sample was unsuccessful, while the second sample was successful, helping patients avoid a repeat procedure. Our young patient (Supplementary Fig. 1 & Table II) had discordant CT and AVS findings. While it is suggested that AVS can be avoided in patients < 35 years with an obvious adenoma on CT,⁽²⁾ the patient's left adrenal enlargement did not constitute a clear adenoma. When both his samples from the right were congruous for right-sided lateralisation, this provided added assurance that the right and left samples had not been switched unintentionally. Having a dedicated radiologist to perform AVS allows greater familiarity and increased confidence. CT imaging before AVS has been shown to improve success rates,⁽²⁸⁾ and can be paramount for identifying variations in both right⁽²⁹⁾ and left adrenal veins.⁽³⁰⁾ In our practice, contrast was not routinely given for CT adrenals unless a lipid-poor adenoma was detected on plain CT. Hence, it is important to specifically request for intravenous contrast to delineate the adrenal veins, which are best seen in the portal venous phase.⁽³¹⁾ Intraprocedural C-arm cone-beam CT may help but is more time-consuming, increases radiation exposure and may not be widely available.⁽²⁷⁾

Factors such as proper catheter equipment and procedural technique should not be understated. As it is more challenging, cannulation of the right adrenal vein should be done first, followed by left and then peripheral cannulation. This reduces time and stress-induced

fluctuations between the three samples. The use of different-shaped catheters for the right and left adrenal veins are also important. We routinely created two 1-mm side holes approximately 2 mm from the catheter tips. This can prevent collapse of the vein and catheter displacement due to the negative pressure created during suctioning while aspirating.⁽²¹⁾ We routinely use the 65-cm 4-Fr C2 Cobra catheter (Cordis, Hialeah, FL, USA) to select the right adrenal vein and the 4-Fr Simmons 2 glide catheter (Terumo, Shibuya, Tokyo, Japan) for the left adrenal vein, and may vary the catheters used depending on the patients' anatomy. Other catheters used include the 5-Fr Cobra, 4-Fr Simmons 1 and 5-Fr Cook Beacon Tip CHG 2.5 (Cook Medical, Bloomington, IN, USA) catheters for the right adrenal vein, and the 5-Fr Cook Beacon Tip CHG 2.5 or Simmons 3 catheter for the left adrenal vein. Microcatheters were not used as they may result in over-selective cannulation of the adrenal veins and increase procedure cost and sampling time. As there is a lack of immediate feedback to the operator regarding catheter positioning and unsuccessful sampling, it is imperative that multimodal imaging be used before and during AVS to allow anatomical confirmation of the adrenal veins and their branches. We suggest using check venograms before and immediately after sampling to evaluate for displacement of the catheter tip.

We acknowledge several limitations to our study. Firstly, the AVS programme implemented included multiple interventions concurrently. As such, it is difficult to elucidate the effect of each intervention on our overall AVS success. Nevertheless, we believe that most of these measures can and should be implemented, and would allow other low-volume centres to achieve similarly high success. Secondly, we used an SI of > 3 as recommended by expert consensus,^(24,32) but some centres recommend > 5 . If we had used > 5 as the cut-off, only one procedure post programme will be considered unsuccessful, as the left adrenal sample was 4.7. Thirdly, while we reported our centre as a low-volume centre with 2.4 procedures per year initially, case numbers have subsequently increased. This reflects the increased confidence of

physicians with the AVS operators and that success begets success. In line with this, there were no differences in patient baseline characteristics before and after the programme, except for a higher proportion of patients with either bilaterally abnormal or normal adrenals. Hence, to improve AVS success, it is important for clinicians to continually refer patients for AVS and increase the experience of their operators.

Finally, we found a discordance between CT and AVS in 35.5% of our patients (Fig. 3), which correlates with a meta-analysis demonstrating a discordance rate of 37.8%.⁽³⁾ This further highlights the crucial role of AVS in accurately identifying patients with unilateral PA. Hence, to ensure that patients with unilateral disease can be offered curative treatment, developing a good AVS programme in each centre is paramount.

In conclusion, with adherence to our measures in a standardised AVS programme, we were able to achieve a high success rate of 100% bilateral cannulation in our low-volume centre. Many of our measures are easy to implement and we believe that our achievement can be replicated in many other centres worldwide. This will help identify more patients with curable unilateral primary aldosteronism.

ACKNOWLEDGEMENTS

We would like to thank the Changi General Hospital laboratory department for their kind assistance with rapid cortisol reporting for adrenal vein sampling, Ms Amanda Tan Hong Dan for her assistance in data analysis, and other interventional radiologists at the institute for performing the AVS procedure.

REFERENCES

1. Young WF. Primary aldosteronism: renaissance of a syndrome. *Clin Endocrinol (Oxf)* 2007; 66:607-18.

2. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 2016; 101:1889-916.
3. Kempers MJE, Lenders JWM, van Oudeusden L, et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. *Ann Intern Med* 2009; 151:329-37.
4. Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. *Lancet Diabetes Endocrinol* 2017; 5:689-99.
5. Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in primary aldosteronism. *Surgery* 2004; 136:1227-35.
6. Teng J, Hutchinson ME, Doery JCG, et al. Role of adrenal vein sampling in primary aldosteronism: the Monash Health experience. *Intern Med J* 2015; 45:1141-6.
7. Vonend O, Ockenfels N, Gao X, et al. Adrenal venous sampling: evaluation of the German Conn's Registry. *Hypertension* 2011; 57:990-5.
8. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. *Lancet Diabetes Endocrinol* 2018; 6:51-9.
9. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. *JAMA Cardiol* 2018; 3:768-74.
10. Burton TJ, Mackenzie IS, Balan K, et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. *J Clin Endocrinol Metab* 2012; 97:100-9.
11. Lenders JWM, Eisenhofer G, Reincke M. Subtyping of patients with primary aldosteronism: an update. *Horm Metab Res* 2017; 49:922-8.

12. Dekkers T, Prejbisz A, Kool LJS, et al. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. *Lancet Diabetes Endocrinol* 2016; 4:739-46.
13. Beuschlein F, Mulatero P, Asbach E, et al. The SPARTACUS Trial: controversies and unresolved issues. *Horm Metab Res* 2017; 49:936-42.
14. Umakoshi H, Tanase-Nakao K, Wada N, et al. Importance of contralateral aldosterone suppression during adrenal vein sampling in the subtype evaluation of primary aldosteronism. *Clin Endocrinol (Oxf)* 2015; 83:462-7.
15. Kline GA, Chin A, So B, Harvey A, Pasieka JL. Defining contralateral adrenal suppression in primary aldosteronism: implications for diagnosis and outcome. *Clin Endocrinol (Oxf)* 2015; 83:20-7.
16. Yoneda T, Karashima S, Kometani M, et al. Impact of new quick gold nanoparticle-based cortisol assay during adrenal vein sampling for primary aldosteronism. *J Clin Endocrinol Metab* 2016; 101:2554-61.
17. Auchus RJ, Michaelis C, Wians FH Jr, et al. Rapid cortisol assays improve the success rate of adrenal vein sampling for primary aldosteronism. *Ann Surg* 2009; 249:318-21.
18. Page MM, Taranto M, Ramsay D, et al. Improved technical success and radiation safety of adrenal vein sampling using rapid, semi-quantitative point-of-care cortisol measurement. *Ann Clin Biochem* 2018; 55:588-92.
19. Blondin D, Quack I, Haase M, Kücükköylü S, Willenberg HS. Indication and technical aspects of adrenal blood sampling. *Rofo* 2015; 187:19-28.
20. Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. *Radiographics* 2005; 25 Suppl 1:S143-58.
21. Young WF, Stanson AW. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? *Clin Endocrinol (Oxf)* 2009; 70:14-7.

22. Puar TH, Loh WJ, Lim DS, et al. Aldosterone--potassium ratio predicts primary aldosteronism subtype. *J Hypertens* 2020; 38:1375-83.
23. Mukherjee JJ, Khoo CM, Thai AC, et al. Type 2 diabetic patients with resistant hypertension should be screened for primary aldosteronism. *Diab Vasc Dis Res* 2010; 7:6-13.
24. Rossi GP, Auchus RJ, Brown M, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. *Hypertension* 2014; 63:151-60.
25. Tan SYT, Ng KS, Tan C, et al. Bilateral aldosterone suppression in patients with right unilateral primary aldosteronism and review of the literature. *J Endocr Soc* 2020; 4:bvaa033.
26. Mengozzi G, Rossato D, Bertello C, et al. Rapid cortisol assay during adrenal vein sampling in patients with primary aldosteronism. *Clin Chem* 2007; 53:1968-71.
27. Chang CC, Lee BC, Chang YC, et al. Comparison of C-arm computed tomography and on-site quick cortisol assay for adrenal venous sampling: a retrospective study of 178 patients. *Eur Radiol* 2017; 27:5006-14.
28. Morita S, Yamazaki H, Sonoyama Y, et al. Successful adrenal venous sampling by non-experts with reference to CT images. *Cardiovasc Intervent Radiol* 2016; 39:1001-6.
29. Scholten A, Cisco RM, Vriens MR, Shen WT, Duh QY. Variant adrenal venous anatomy in 546 laparoscopic adrenalectomies. *JAMA Surg* 2013; 148:378-83.
30. Siebert M, Robert Y, Didier R, et al. Anatomical variations of the venous drainage from the left adrenal gland: an anatomical study. *World J Surg* 2017; 41:991-6.
31. Noda Y, Goshima S, Nagata S, et al. Visualization of right adrenal vein: comparison with three phase dynamic contrast-enhanced CT. *Eur J Radiol* 2017; 96:104-8.
32. Freel EM. Adrenal vein sampling: is there now a consensus? *Clin Endocrinol (Oxf)* 2015; 82:35-6.

FIGURES




Fig. 1 (a) Chart shows the number of AVS procedures done each year from 1998–2019, demonstrating an increase in procedures after programme implementation in 2015 and an increase in successful AVS procedures; from 2015, rapid cortisol reporting was done and five patients with an initial failed AVS underwent successful repeat sampling. (b) Chart shows the number of diagnoses of unilateral or bilateral primary aldosteronism made after AVS procedures. Indeterminate results were mostly due to failed AVS procedures, while two cases in 2019 had successful AVS but bilaterally low aldosterone levels, and subsequently had a conclusive diagnosis on repeat AVS in a separate procedure. AVS: adrenal vein sampling




Fig. 2 Flowchart shows the number of patients and AVS procedures performed before and after programme implementation. One patient who had a failed AVS procedure before programme implementation subsequently had a successful procedure after programme implementation. AVS: adrenal vein sampling; PA: primary aldosteronism




Fig. 3 Pie chart shows that results were concordant (white) and discordant (shaded) between AVS and CT imaging in 76 patients who underwent successful AVS. AVS: adrenal vein sampling; CT: computed tomography; CT bilat Ab: bilaterally abnormal adrenal glands on CT; CT bilat N: bilaterally normal adrenal glands on CT

APPENDIX**Supplementary Table I. Results of 104 AVS procedures done before and after programme implementation.**

Parameter	No. (%) / median (interquartile range)		p-value
	Before programme (n = 41)	After programme (n = 63)	
Bilaterally successful AV cannulation	18 (43.9)	63 (100.0)	< 0.001
Failed cannulation			< 0.001
Right AV	12 (29.3)	0 (0)	
Left AV	1 (2.4)	0 (0)	
Bilateral AV	10 (24.4)	0 (0)	
Selectivity index			
Right AV	3.9 (1.0–21.5)	23.5 (17.1–32.7)	< 0.001
Left AV	10.0 (4.5–19.4)	18.1 (12.3–23.8)	0.003
Repeat AVS prompted by rapid cortisol	0 (0)	5 (7.9)	0.15
2nd right AV correct	0 (0)	8 (12.7)	0.021
Lab result error	8 (19.5%)	0 (0)	< 0.001

AV: adrenal vein



Supplementary Fig. 1 CT image of a 34-year-old man with confirmed primary aldosteronism showed left adrenal gland thickening (arrow). However, AVS showed lateralisation to the right with left-sided suppression. The patient was cured of primary aldosteronism after a right adrenalectomy.

Supplementary Table II. Results of AVS samples obtained from the patient in Supplementary Fig. 1 show elevated lateralisation ratios for the right adrenal gland.

Parameter	Right adrenal #1	Right adrenal #2	Peripheral	Left
Aldosterone (pmol/L)	121,475	108,135	1,219.1	25,414
Cortisol (nmol/L)	19,226	19,350	792	17,271
Aldosterone-cortisol ratio	6.32	5.59	1.54	1.47

Lateralisation ratio is 4.3 (using right #1) and 3.8 (using right #2). Contralateral suppression on the left is 0.96.